Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Boehringer Ingelheim
Chinese Patent Office
Deloitte
McKinsey
Fish and Richardson
Chubb
Mallinckrodt

Generated: October 21, 2018

DrugPatentWatch Database Preview

EOVIST Drug Profile

« Back to Dashboard

When do Eovist patents expire, and what generic alternatives are available?

Eovist is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in EOVIST is gadoxetate disodium. One supplier is listed for this compound. Additional details are available on the gadoxetate disodium profile page.

Drug patent expirations by year for EOVIST
Generic Entry Opportunity Date for EOVIST
Generic Entry Date for EOVIST*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EOVIST

US Patents and Regulatory Information for EOVIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for EOVIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0405704/01 Switzerland ➤ Sign Up FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE
C/GB05/021 United Kingdom ➤ Sign Up PRODUCT NAME: GADOXETIC ACID, OPTIONALLY IN THE FORM OF A SALT; REGISTERED: SE 18929 20040326; SE 18930 20040326; UK PL 00053/0348 20041110; UK PL 00053/0349 20041110
0182 Netherlands ➤ Sign Up 300182, 20100627, EXPIRES: 20150626
00182 Netherlands ➤ Sign Up PRODUCT: GADOXETINEZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER HET NATRIUMZOUT. FIRST AUTHORIZATION NO/DATE: 1829 AND 18930, 20040326 (SE); NATIONAL AUTHORIZATION NO/DATE: RVG 31393 AND 31394, 20050113
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Boehringer Ingelheim
Chinese Patent Office
Deloitte
McKinsey
Fish and Richardson
Chubb
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.